Bio/Pharma Business

Pharmaceutical Technology marks 40 years of publishing.

In Lazard's Global Healthcare Leaders 2017 survey, most respondents said pricing and reimbursement were the most significant challenge, but nearly half of the pharma executives who responded see value-based pricing as having the greatest impact on the business, potentially even more than scientific breakthroughs.

A rigorous approach to industrial security is essential for protecting intellectual property and product integrity in connected pharmaceutical operations.

New study will reveal bio/pharma practices and performance on quality issues.

New study shows China biopharma companies face staffing shortages.

A blog posted on Health Affairs on March 7, 2017 presents a study that tested PhRMA’s long-standing argument that high prices for drugs fund research and development in the pharmaceutical industry.

Drug type, potential sales, and ownership factor in the race to get drugs to market.

The authors discuss regulatory and patent issues with combination products.

The trends in the year 2017 will present the industry with new challenges, and companies will be able to meet them successfully if they focus on the issues at hand.

Drug companies are pushing Congress to action on funding for FDA programs and staff to expedite drug reviews and approvals.

Pharmaceutical Technology spoke with Tommy Fanning, head of biopharmaceuticals for IDA Ireland, to get a perspective on how Brexit may affect the pharmaceutical industry.

Top C-suite leaders are already tuning their long-range planning, hiring practices, and business systems for elasticity. Are you ready?

Translating campaign promises to predictions for bio/pharma is difficult, but optimism prevails.

Healthcare policies, R&D investments, and drug approvals will test bio/pharma.

Estimates that global medicine spending will reach nearly $1.5 trillion by 2021 and the types of therapies and use of innovator versus generic drugs, will vary by region.

As Europe’s bio/pharma market learns that breaking up is hard to do, it also must address productivity, regulatory, and drug pricing challenges.

Rookie API developers beat pharma at its own game.

Survey reveals optimism, discontent, and a desire for better career opportunities.

Europe-based bio/pharma employees are unified on satisfaction with employment conditions-and dissatisfaction with salaries.

Biopharma proponents argue for FDA resources, Cures legislation, and science-based drug regulation.

Steep price increases for a popular drug have created patient and Congressional backlash.

A KPMG survey reveals that approximately 84% of pharma and medical device executives plan to add jobs in next 12 months.

PharmTech’s 2016 survey shows general satisfaction with existing solid-dose and parenteral manufacturing equipment, and slow adoption of continuous manufacturing processes.

Quality, innovation, and new approval pathways open drug development options for the Chinese market, including injectable contract manufacturing.

Patheon launches initial public offering to repay outstanding notes and expenses.

CPhI Pharma Awards seek nominations for excellence in development and manufacturing.

Investment in talent and infrastructure, more quality-by-design skills, and increased communication with global regulators will be needed to combat compliance issues at API and drug manufacturing facilities in India.

Insight on the new regulatory framework from the China Food and Drug Administration

PharmTech sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.

AMRI’s acquisition of Euticals expands its API development and manufacturing business.